Fierce Pharma

NOVEMBER 5, 2024

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial.

Medical 291

Medical 291

pharmaphorum

NOVEMBER 5, 2024

Disc Medicine has charted a route to market for bitopertin, its drug candidate for rare disease erythropoietic protoporphyria (EPP), after meeting with the FDA.Shares in the company gained almost 24% after it announced that the end of phase 2 meeting with the US regulator had firmed up plans for a phase 3 trial of bitopertin in EPP, as well as the potential for accelerated approval.

Medicine 94

Medicine Marketing 94

Fierce Pharma

NOVEMBER 5, 2024

With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta thalassemia, “there has never been a more exciting time to be at Vertex,” c | With its first Casgevy revenues in the books, Vertex lifted its full-year sales outlook as it turns its attention to two product launches in 2025, including an expected new entrant in the pain market.

Patients 263

Patients Sales Marketing 263

MedCity News

NOVEMBER 5, 2024

Digital twin technology can serve as an effective complement to some of the exciting advancements occurring in the metabolic health space, such as new generations of continuous glucose monitors and a slew of GLP-1s, according to Lisa Shah, chief medical officer at Twin Health. The post Why Digital Twin Technology Could Help Maximize GLP-1 Efficacy appeared first on MedCity News.

Medical 98

Medical Management Biopharma 98

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

Fierce Pharma

NOVEMBER 5, 2024

Despite witnessing modest growth in demand over the past three months, Apellis Pharmaceuticals’ complement inhibitor for geographic atrophy (GA), Syfovre, may have hit a performance “nadir” in 2024 | Over the latest earnings stretch, Apellis' Syfovre saw sales down about 2% from the previous quarter despite an overall demand increase of about 7%.

Sales 240

Sales Pharmaceutical 240

MedCity News

NOVEMBER 5, 2024

Reimbursement models that align primary care with behavioral health offer low-income provider organizations serving rural Americans and other vulnerable populations an opportunity to enhance coordination and improve outcomes while generating sorely needed revenue. The post How to Align Primary Care With Behavioral Health appeared first on MedCity News.

Physicians 99

Physicians Patients Healthcare Healthcare 99

pharmaphorum

NOVEMBER 5, 2024

AstraZeneca's shares have fallen more than 8% on speculation about an anti-corruption probe in China, its second-largest market, wiping around $14 billion off its value.The sell-off appears to have been prompted by an article in Chinese financial media outlet Yicai which suggested that "dozens of senior executives" at AZ's Chinese subsidiary have been implicated in an ongoing insurance fraud case.

Insurance 96

Insurance Media Marketing 96

Fierce Pharma

NOVEMBER 5, 2024

As the U.K. works to pump fresh cash into the local biopharma scene, London’s Accord Healthcare is capitalizing on the government’s renewed willingness to chip in. | Flush with a 50 million pound sterling ($65 million) joint investment deal from the U.K., Accord—one of Europe's top makers of generic chemotherapies—is embarking on an expansion of its Fawdon drug manufacturing facility in Newcastle upon Tyne, England.

Biopharma 198

Biopharma Manufacturing Healthcare Healthcare 198

pharmaphorum

NOVEMBER 5, 2024

Therapeutic or focused ultrasound began being applied to neurologic conditions less than a decade ago, but its potential in a wide spectrum of brain applications is high. In today’s podcast, web editor Nicole Raleigh speaks with Dr Neal Kassell, chair and founder of the Focused Ultrasound Foundation and previously a neurosurgeon, who created the Foundation in 2006 to improve the lives of millions of people with serious medical disorders by accelerating the development and adoption of focused ult

Medical 93

Medical 93

Fierce Pharma

NOVEMBER 5, 2024

AstraZeneca’s stock price dropped by 8.4% during Tuesday’s trading in London after a local report fueled fears of a potentially escalating insurance fraud investigation in China. | AstraZeneca’s stock price dropped by 8.4% during Tuesday’s trading in London after a report fueled fears of a potentially escalating insurance fraud investigation in China.

Insurance 197

Insurance 197

Advertisement

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

Sales

MedCity News

NOVEMBER 5, 2024

Employers are prioritizing mental wellbeing programs, but employees say they need financial wellbeing support, according to a survey from WTW. The post WTW: There’s A Disconnect Between Employers and Employees on Wellbeing Programs appeared first on MedCity News.

95

95

pharmaphorum

NOVEMBER 5, 2024

Beam shines a light on phase 1/2 data with its base editing candidate for sickle cell disease ahead of a full presentation at ASH next month

101

101

MedCity News

NOVEMBER 5, 2024

The death wasn’t due to Beam Therapeutics’ sickle cell disease therapy, BEAM-101, but was instead attributed to the preconditioning treatment needed before the genetic medicine is infused. A different Beam program in preclinical development could avoid the need for toxic preconditioning; data from both programs will be presented during the upcoming American Society of Hematology annual meeting.

Medicine 92

Medicine Biopharma Pharma 92

PharmaVoice

NOVEMBER 5, 2024

Sernova’s technology helped type 1 diabetes patients achieve insulin independence in early- and mid-stage trials.

Patients 98

Patients 98

Advertisement

MedCity News

NOVEMBER 5, 2024

Healthcare must be more than a transactional experience. The focus must be on relationships, continuity, and coordination. The post Why Retail isn’t the Future of Healthcare appeared first on MedCity News.

Retail 92

Retail Healthcare Healthcare Doctors 92

pharmaphorum

NOVEMBER 5, 2024

Journey Medical has claimed FDA approval for its Emrosi therapy for rosacea, which it thinks could become a "standard of care" drug for the common skin disorder.The new capsule formulation of the antibiotic minocycline hydrochloride has been cleared by the US regulator to treat the inflammatory lesions caused by rosacea – which causes flushing or long-term redness and pustules on the face – in adults.

FDA 69

FDA Medical 69

MedCity News

NOVEMBER 5, 2024

Employers are prioritizing mental wellbeing programs, but employees say they need financial wellbeing support, according to a survey from WTW. The post WTW: There’s A Disconnect Between Employers and Employees on Wellbeing Programs appeared first on MedCity News.

70

70

Pharmaceutical Commerce

NOVEMBER 5, 2024

JAMA study indicates Canada may have a more resilient drug supply chain or different thresholds for reporting and responding to issues compared with the United States.

59

59

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

MedCity News

NOVEMBER 5, 2024

As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers. The post Reducing Clinical and Staff Burnout with AI Automation appeared first on MedCity News.

Healthcare Provider 67

Healthcare Provider Healthcare Healthcare 67

PharmaTech

NOVEMBER 5, 2024

In the wake of the Food and Drug Administration's (FDA's) latest guidance on nitrosamine contamination, ensuring compliance and safeguarding pharmaceutical products is more critical than ever. This ebook provides a comprehensive roadmap for understanding nitrosamine risks and offers actionable strategies to mitigate potential impurities. Through expert insights from Adare Pharma Solutions, you’ll learn how to remain compliant, identify risks, and implement cutting-edge strategies for nitrosamine

Food and Drug Administration 52

Food and Drug Administration Pharmaceutical products Food FDA 52

Contrarian Sales Techniques

NOVEMBER 5, 2024

If you’re like me, living in Kuantan, Pahang, and raising a small family while working in the private sector, you know budgeting can feel like a never-ending task. Fortunately, we have new tools to help us get a clearer picture of our monthly living costs, especially for the essentials. Enter MyPAKW , the calculator developed by Malaysia's Department of Statistics ( DOSM ).

Transportation 52

Transportation Food Education Healthcare 52

PharmExec

NOVEMBER 5, 2024

At the Financial Times’ Global Pharma and Biotech Summit 2024, Christophe Weber, president and CEO, Takeda, discusses how trust and collaboration between the biopharma industry and stakeholders can be implemented to support successful healthcare transformation.

Pharma 52

Pharma Biopharma Healthcare Healthcare 52

Advertiser: ZoomInfo

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

Competition

Contrarian Sales Techniques

NOVEMBER 5, 2024

Understanding the Malaysian Banking Scene In Malaysia, banking isn’t just about selling products—it’s about building trust and understanding each customer’s unique needs. As a sales professional in this market, connecting with clients goes beyond financial discussions; it’s about forming genuine relationships. Whether it’s helping someone with a personal loan, guiding a small business owner, or introducing a client to Islamic banking products, a thoughtful approach is key.

Sales 52

Sales Marketing Ethics Insurance 52

European Pharmaceutical Review

NOVEMBER 5, 2024

New data presented at Psych Congress 2024 has shown that the olanzapine long-acting injectable (LAI) TEV-‘749 / mdc-TJK demonstrated “significant improvement” in social functioning and quality of life in adults with schizophrenia. This was based on findings from the initial period (up to week 8) of the Phase III SOLARIS trial. According to Medincell, TEV-‘749 could be the first long-acting olanzapine medication with a favourable safety profile, because “other LAIs of olanzapine have been associa

Side effects 52

Side effects Medical Safety Medicine 52

Pharmaceutical Commerce

NOVEMBER 5, 2024

In the third part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Delphine Perridy, chief commercial officer, Envirotainer, discusses the significant increase in demand for sustainable practices and outlines the company's initiatives in this area.

Pharma 52

Pharma 52

Pharmaceutical Technology

NOVEMBER 5, 2024

This initiative brings together UK Biobank, Genomics England, NHS England, and Oxford Nanopore to accelerate genomics-based research in the UK.

59

59

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

PharmExec

NOVEMBER 5, 2024

Ted Sweetser, VP, Ad Partnerships and Strategy, PurpleLab discusses the need to balance personalized targeting with the ethical imperative to protect consumer privacy.

Ethics 52

Ethics 52

pharmaphorum

NOVEMBER 5, 2024

Cancer Research UK awards £5.

93

93

Pharmaceutical Technology

NOVEMBER 5, 2024

The EMA has accepted a MAA for Alvotech and Advanz Pharma’s AVT05, a proposed biosimilar to Johnson & Johnson’s (J&J) Simponi (golimumab).

52

52

PharmExec

NOVEMBER 5, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Pharma 52

Pharma 52

Advertisement

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

Sales